Newsmeme!
Discover News you didn't know existed
Neoplasm
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial For Treatment And Prevention Of ...
Published February 4, 2010, 6:54 am, PharmaceuticalOnline
Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis ...
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial For Treatment Of Recurrent Venous ...
Published February 4, 2010, 5:51 am, Medical News Today
Daiichi Sankyo Company, Limited (TSE: 4568), announced that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis ...
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of ...
Published February 3, 2010, 8:07 am, redOrbit
TOKYO and EDISON, N.J., Feb. 3 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor.
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of ...
Published February 3, 2010, 5:00 am, PR Newswire via Yahoo! Finance
Daiichi Sankyo Company, Limited , announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic complications in patients with deep vein thrombosis and/or pulmonary embolism .
Press Release
Published February 3, 2010, 4:25 am, PharmiWeb
TOKYO, Japan and EDISON, New Jersey, February 3 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it hasinitiated a new large-scale pivotal Phase III trial for edoxaban, itsinvestigational oral Factor Xa inhibitor.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |